MYDA Advisors LLC Invests $136,000 in EQRx, Inc. (NASDAQ:EQRX)

MYDA Advisors LLC acquired a new position in shares of EQRx, Inc. (NASDAQ:EQRX – Get Rating) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 20,000 shares of the company’s stock, valued at approximately $136,000.

Other institutional investors also recently bought and sold shares of the company. Advisor Group Holdings Inc. purchased a new stake in shares of EQRx during the fourth quarter worth $67,000. Brown Advisory Inc. acquired a new position in shares of EQRx during the fourth quarter worth $84,000. Texas Yale Capital Corp. acquired a new position in shares of EQRx during the fourth quarter worth $136,000. Cannon Global Investment Management LLC acquired a new position in shares of EQRx during the fourth quarter worth $171,000. Finally, Northern Trust Corp acquired a new position in shares of EQRx during the fourth quarter worth $329,000. 69.24% of the stock is currently owned by institutional investors and hedge funds.

A number of equities analysts recently commented on the stock. Cowen assumed coverage on shares of EQRx in a research note on Friday, April 22nd. They set an “outperform” rating for the company. Cowen assumed coverage on shares of EQRx in a research note on Friday, April 22nd. They set an “outperform” rating for the company. Finally, Jefferies Financial Group initiated coverage on shares of EQRx in a research note on Friday, March 18th. They set a “buy” rating and a $5.60 target price for the company.

NASDAQ EQRX traded up $0.04 during trading hours on Wednesday, hitting $4.80. The company had a trading volume of 13,938 shares, compared to its average volume of 1,230,781. EQRx, Inc. has a 1-year low of $2.63 and a 1-year high of $11.10. The firm has a 50 day moving average of $4.23.

EQRx (NASDAQ:EQRX – Get Rating) last released its quarterly earnings data on Friday, May 13th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.34. As a group, sell-side analysts anticipate that EQRx, Inc. will post -1.02 earnings per share for the current year.

EQRx Profile (Get Rating)

EQRx, Inc, a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC.

Read More